Results 151 to 160 of about 7,770 (204)

An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany. [PDF]

Front Public Health
Raitner I, Müller B, Vijayan A, Zimmermann L, Bramlage P, Ness NH, Müller M.   +6 more
europepmc   +1 more source

Savings from biosimilars and Medicare formulary access. [PDF]

Health Aff Sch
Axelsen K, Courmier D, Bai G, Maini L.
europepmc   +1 more source

Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis. [PDF]

Saudi Pharm J
Shan H, Guo Z, Ye X, Du Q, Liu J, Wang M.   +5 more
europepmc   +1 more source

Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review. [PDF]

Endocrinol Diabetes Metab
Hindley B, Wright S, Ooi C, Da Costa R, Cope L.   +4 more
europepmc   +1 more source

Biosimilars [PDF]

, 2013
openaire   +1 more source

Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]

Pharmaceuticals (Basel)
Ponamarev VS.
europepmc   +1 more source

Posterior segment inflammation with venous involvement following a switch to a ranibizumab biosimilar (Ximluci®): a case report. [PDF]

Am J Ophthalmol Case Rep
Conte S, Nassisi M, Mainetti C, Seregni L, Viola F.   +4 more
europepmc   +1 more source

Determinants of access to anticancer medicines in South Asia: a multimethod study. [PDF]

BMJ Open
Shukar S, Hussain I, Iqbal A, Rahimi A, Shirol GM, Shirzad I, Tenzin J, Dewan SMR, Kumari Mishra S, Saeed A, Babar ZU, Yang C, Fang Y.   +12 more
europepmc   +1 more source

Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study. [PDF]

Sci Rep
Song JR, Park UC, Lee CS, Cho JJ, Kim JY, Baek SC, Jeong A, Sharma A, Kim JH, Sagong M, Woo SJ, International Retina Biosimilar Study Group (Inter BIOS Group).   +11 more
europepmc   +1 more source

Expanding Horizons in Severe Asthma: Anti-IgE Biosimilars and the Redefinition of Patient Selection. [PDF]

Allergy Asthma Immunol Res
Yun JE, Song WJ.
europepmc   +1 more source